Clinical Trials Browser

INDUSTRY × Neoplasms × nilotinib × Clear all

Neoplasms

NCT01863745 2024-08-19

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Phase 2 Completed

15 enrolled 7 charts

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT02627677 2021-11-26

OPTIC-2L

Phase 3 Terminated

44 enrolled 22 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01289028 2017-01-02

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Phase 3 Completed

125 enrolled 11 charts

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Phase 1 Completed

14 enrolled

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

Clinical Trials

XS003-11

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

OPTIC-2L

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib